Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma (The Oncologist (2009) 14, (900-908) DOI: 10.1634/theoncologist.2009-0058);Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma

Oncologist

Volumn 14, Issue 9, 2009, Pages 900-908

  Hama, Takanori ^a   Yuza, Yuki ^a   Saito, Yoshimichi ^a,b   O Uchi, Jin ^a   Kondo, Shu ^a   Okabe, Masataka ^a   Yamada, Hisashi ^a   Kato, Takakuni ^a   Moriyama, Hiroshi ^a   Kurihara, Satoshi ^a   Urashima, Mitsuyoshi ^a,b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

EGFR; Head and neck squamous cell carcinoma; HNSCC; Phosphorylation; Prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE INSERTION; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

EID: 70349436013     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0058erratum     Document Type: Erratum

References (24)

1. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578. (Pubitemid 43209104)
2. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500. (Pubitemid 38720929)
3. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
4. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-7356. (Pubitemid 36025259)
5. Rubin Grandis J, Melhem MF, GoodingWEet al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-832. (Pubitemid 28280548)
6. Muller S, Su L, Tighiouart M et al. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: Predictive and prognostic correlation. Cancer 2008;113:97-107. (Pubitemid 351976391)
7. Azam M, Raz T, Nardi V et al. A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online 2003;5:204-210. (Pubitemid 38097516)
8. Yuza Y, Glatt KA, Jiang J et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther 2007;6:661-667. (Pubitemid 47328344)
9. 2+ channel. Circ Res 2008;102:1378-1388.
10. Temam S, Kawaguchi H, El-Naggar AK et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25:2164-2170. (Pubitemid 46954638)
11. Takano T, Ohe Y, Sakamoto H et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23: 6829-6837. (Pubitemid 46260269)
12. Bell DW, Lynch TJ, Haserlat SM et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23: 8081-8092. (Pubitemid 46657411)
13. Chen Z, Feng J, Saldivar JS et al. EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: One-third of doublets occur at five pairs of amino acids. Oncogene 2008;27:4336-4343. (Pubitemid 352010002)
14. Lee JW, Soung YH, Kim SY et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11: 2879-2882. (Pubitemid 40525187)
15. Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 2006;19:634-640.
16. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006;42:109-111. (Pubitemid 41814540)
17. Sok JC, Coppelli FM, Thomas SM et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-5073. (Pubitemid 44453332)
18. Fischer C, Zlobec I, Stöckli E et al. Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas. Hum Pathol 2008;39:1527-1534.
19. Seethala RR, Gooding WE, Handler PN et al. Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Cancer Res 2008;14:1303-1309.
20. Sonobe M, Nakagawa M, Takenaka K et al. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl- Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. J Surg Oncol 2007;95:63-69. (Pubitemid 46122720)
21. Masago K, Fujita S, Hatachi Y et al. Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. Cancer Sci 2008;99: 2295-2301.
22. Takano T, Fukui T, Ohe Y et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: A historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008;26:5589-5595.
23. Hoshino M, Fukui H, Ono Y et al. Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology 2007;74:15-21. (Pubitemid 46742314)
24. Magkou C, Nakopoulou L, Zoubouli C et al. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res 2008;10:R49.